Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Asad Mohammad

Clinical Cardiac Electrophysiology New York, NY Doctor of Osteopathy

NPI 1609193754 CMS profile 636655

1111 Amsterdam Ave # Areaj, New York, NY 10025

Open in the dashboard

General payments

$76,002

821 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$34,902 paid to institutions, not to them · program years 2022–2023

Through program year 2025, Asad Mohammad of New York, NY is reported in the CMS Open Payments database as having received $76,002 across 821 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $34,902 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,400 56
2024 General $2,992 72
2023 General $8,579 108
2022 General $30,257 185
2021 General $16,991 196
2020 General $7,247 131
2019 General $7,537 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asad Mohammad
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Asad Mohammad were reported at $2,400. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Asad Mohammad Clinical Cardiac Electrophysiology median Middle half National median
2019 $7,537 $2,361 $585–$8,260 $163
2020 $7,247 $993 $247–$4,351 $114
2021 $16,991 $1,185 $326–$4,739 $132
2022 $30,257 $2,073 $554–$6,789 $149
2023 $8,579 $2,568 $759–$8,159 $160
2024 $2,992 $2,557 $703–$7,403 $164
2025 $2,400 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $38,952 258 payments
  2. Aziyo Biologics, Inc. $14,098 14 payments
  3. Boston Scientific Corporation $6,220 148 payments
  4. Biosense Webster, Inc. $5,627 151 payments
  5. Abbott Laboratories $2,866 40 payments
  6. Medtronic, Inc. $2,125 32 payments
  7. Stereotaxis Inc $1,271 26 payments
  8. Janssen Pharmaceuticals, Inc $1,254 49 payments
  9. Cardiva Medical, Inc. $835 10 payments
  10. AstraZeneca Pharmaceuticals LP $436 11 payments
  11. Other $2,319 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $34,939 743 payments
  2. Travel and Lodging $18,013 44 payments
  3. Consulting Fee $9,394 4 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $5,900 4 payments
  5. Honoraria $4,530 2 payments
  6. Education $1,962 21 payments
  7. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,250 1 payment
  8. Entertainment $14 2 payments
Products named General payments · program years 2019–2025
  1. ECM Patch,Pouch $14,098 14 payments
  2. BioMonitor $9,182 67 payments
  3. Solia $8,513 46 payments
  4. Rivacor $7,866 47 payments
  5. Edora $7,866 47 payments
  6. Acticor $7,866 47 payments
  7. Edora 8 DR-T $6,620 23 payments
  8. Acticor 7 VR-T DX $6,333 26 payments
  9. Rivacor 7 DR-T $5,852 20 payments
  10. Carto 3 $5,429 176 payments
  11. Other $29,596 498 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,108

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$291,572

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

32.9%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 261 $211,283
Xarelto Rivaroxaban Brand 66 $60,217
Entresto Sacubitril/Valsartan Brand 11 $11,246
Metoprolol Succinate Generic 452 $6,214
Amiodarone Hcl Generic 96 $1,449
Atorvastatin Calcium Generic 27 $321
Carvedilol Generic 38 $165
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 15 $127
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 12 $125
Amlodipine Besylate Generic 37 $110

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$216,189

Medicare's payments for the services billed

Medicare patients

797

Average age 78

Services billed

2,530

405 women, 392 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
Arthritis 59%
Atrial fibrillation 55%
Diabetes 52%
Heart failure 51%
Chronic kidney disease 49%
COPD 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $59
$59 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $56
$56 66 —
ELIQUIS
  • PFIZER INC. $25
  • E.R. Squibb & Sons, L.L.C. $23
$47 261 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $30
$30 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $30
$30 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

821 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record